Table 2.
Characteristics of selected studies
| Study (year) | Study design | Inclusion criteria | Number of patients | Age (years) | Duration of dialysis | Efficacy of dialysis (Kt/V) | Dosage, route, and frequency (O3FA amount) | Duration | Severity assessment | Pruritus score (before→after), experimental control |
|---|---|---|---|---|---|---|---|---|---|---|
| Begum et al. 2004 [27] | RCT | HD | FO: 12 SO: 10 |
FO: 61.2±19.42 SO: 49.25±18.12 |
FO: 4.84±3.35 SO: 5.88±4.64 |
NA | FO, 6 g, oral, daily (4.36 g) | 16 weeks | DPS | FO: 16.7±11.4→8.9±9.2 SO: 17.6±8.8→13.1±5.6 |
| Ghanei et al. 2012 [48] | RCT Cross-over |
HD | O-P: 11 P-O: 11 |
O-P: 59.90±14.82 P-O: 53.09±13.08 |
O-P: 3.81±2.04 P-O: 5.09±4.88 |
O-P: 1.24±0.05 P-O: 1.41±0.27 |
FO, 1 g, oral, TID (0.9 g) | 20 days | DPS | O-P: 20.3±5.28→6.4±5.13 P-O: 17.0±6.84→14.4±5.73 |
| Lahiji et al. 2018 [49] | RCT Cross-over |
CAPD | O-P: 20 P-O: 20 |
O-P: 62.1±11.6 P-O: 61.9±10.8 |
NA | NA | O3FA, 3 g, oral, daily | 4 weeks | VAS | O-P1: 6.4±1.5→3.38±1.5 P-O1: 4.2±2.4→3.72±1.4 |
| Peck et al. 1996 [26] | RCT | HD | FO: 8 OO: 9 SO: 8 |
FO: 54.8±16.2 OO: 45.6±17.4 SO: 49.5±17.2 |
NA | NA | FO, 6 g, oral, daily | 8 weeks | DPS | FO: 8.79±4.65→4.95±4.02 OO: 6.63±2.82→3.62±2.13 SO: 8.18±4.49→8.06±4.85 |
| Shayanpour et al. 2019 [50] | RCT | HD | O: 32 P: 32 |
O: 51.91±6.586 P: 56.25±8.865 |
NA | NA | O3FA, 2 g, daily, oral | 3 weeks | 5-DIS | O: 12.97±1.71→6.66±1.24 P: 14.37±1.37→12.78±1.80 |
Data are presented as mean±SD. CAPD: Continuous ambulatory peritoneal dialysis, 5-DIS: 5-D Itch Scale, DPS: Duo Pruritus Score, FO: Fish oil, HD: Hemodialysis, NA: Not available, O: The omega-3 group, O3FA: Omega-3 fatty acid, OO: Olive oil, P: Placebo group, RCT: Randomized controlled trial, SO: Safflower oil, TID: Ter in die, VAS: Visual Analog Scale, SD: Standard deviation